
How in vivo HSC editing could upend gene therapy costs
Nature’s Biotechnology feed spotlights a study that pushes gene therapy toward the clinic’s front door: antibody‑modified lipid nanoparticles that edit human haematopoietic stem cells inside the bone marrow. If the approach holds up beyond preclinical work, in vivo HSC editing could remove the need for cell harvests, bespoke manufacturing, and reinfusion cycles that define today’s […]







